Hematology Continuing Education

Continuing Education on Hematology

The recent years have witnessed major advances in the treatment of benign rare blood disorders such as hemophilia, sickle cell disease (SCD), and cold agglutinin disease (CAD). Moreover, new guidelines have been developed for the diagnosis and management of these blood disorders. Clinicians including hematologists and emergency department physicians need to remain up to date on the various aspects of management of these hematological disorders to diagnose, treat, and manage associated complications. Moreover, access to novel therapies remains challenging due to payer restrictions including step therapy policies. Hematologists and their care team need education on streamlining the prior authorization processes to prevent treatment delays.

 

Hematology CE/CME Activities

The CME Outfitters Hematology Hub is designed to provide clinicians with the latest clinical practice guidelines, diagnostic strategies and tools, scientific updates on current and emerging therapies, latest guidelines to optimize the management of hematological disorders, and strategies to streamline prior authorization process. In addition, the Hematology Hub also provides patient education tools to empower patients to make informed decisions about their care and to navigate the prior authorization process.

Jump to:

 

Live & On-Demand Webcasts CMEOCast Clinician Resources Patient Resources   Partners

Diagnosis and Individualized Management of von Willebrand Disease: Expert Perspectives on Synthesizing and Contextualizing the Evidence

 

 

Participate Now   Download the Transcript  

Von Willebrand disease (VWD), the most common inherited bleeding disorder, is caused by a deficiency in or dysfunction of von Willebrand factor (VWF),and results in disrupted hemostasis. VWD affects approximately 1% of individuals and can cause a myriad of symptoms, ranging from mucocutaneous bleeding in patients who are mildly affected to gastrointestinal bleeding and joint arthropathy in patients with severe disease. Despite its relatively high prevalence, early diagnosis and effective treatment of VWD have been challenging due to a need for education that contextualizes recently published, multidisciplinary guidelines and provides strategies for incorporating them into practice, including showcasing the role of prophylaxis in patients with severe VWD to prevent significant bleeding and arthropathy.

Understanding Anemia in Patients with CKD: From Diagnosis to Data on Emerging Agents

 

 

Participate Now  

In this CME Outfitters On-Demand webcast, two experts in CKD will discuss the pathophysiology and signs and symptoms of anemia in patients with CKD, review current best practices for managing anemia in CKD, and explore the safety and efficacy of emerging HIF-PHIs.

Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced CSPC

 

Participate Now  

Despite the development of investigational and therapeutic options for prostate cancer, a lack of consensus among clinicians regarding patient management in early disease stages remains. Patients with locally advanced or metastatic castration-sensitive prostate cancer should receive androgen deprivation therapy (ADT) after definitive therapy, and it is imperative that clinicians consider luteinizing hormone releasing hormone (LHRH) antagonists in patients with major adverse cardiovascular events (MACE) risk factors. Additionally, must weigh factors that might negatively impact ADT adherence against the choice of ADT. This CMEOCast episode will aim to improve knowledge and competence in integrating the latest data on the management of patients with early-stage prostate cancer by evaluating strategies for its management and differentiating the potential for adverse effects between androgen deprivation therapies

Management of Patients with Metastatic Castration-Sensitive Prostrate Cancer

 

Participate Now  

In this CME Outfitters podcast, expert faculty focus on patient selection criteria for second-generation antiandrogen therapy and the role of molecular testing risk stratification of patients with metastatic CSPC.

Clinician Resources

Patient Resources

Partners

Maya Bloomberg is a board certified Family Nurse Practitioner at Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital. She earned both her bachelors and masters of science in nursing degrees from University of Miami. She has worked as a hematology Nurse practitioner for over 7 years, specializing in sickle cell and bleeding disorders, which shed light on the significant health and racial disparities, and led her to become a vocal advocate for health equity. This led her to create a social media page @theHemeNP devoted to providing reliable information to sickle cell patients so they can better advocate for their health, with hopes of bridging this disparity.

Visit Website  

Discover additional accredited CME/CE activities and patient resources on the Virtual Education Hub.

Visit the Hub